This report maps the global GLP-1 and metabolic competitive landscape across 628 active programs as of August 2026. The analysis spans pipeline composition by phase and origin, sales and route-of-administration breakdowns, indication expansion beyond T2D and obesity, deal flow patterns, weight-loss benchmarks, and near-term catalysts.

Late-stage entrants are stacking up behind Novo and Lilly, but the branded U.S. market remains a duopoly. Chinese firms now field nearly twice the U.S. pipeline (323 vs 155 programs), widening to 2.9x at Phase 3. Leading injectables cluster at 20-28% weight loss while orals trail at 12-14%, pushing differentiation off raw efficacy toward route, dosing, and quality of weight loss.

The combination pipeline contains 124 unique target pairings, but only incretin co-agonists have matured past early stage. Muscle-sparing combinations are emerging as the next competitive frontier, with roughly 70 programs claiming the positioning. Real-world persistence remains a core challenge: about half of obesity patients stop treatment within six months, driven primarily by cost (43-68% of discontinuations) and side effects.

China has become the fast-follower engine the West sources its next GLP-1s from, with licensing-in deals accelerating since 2024. Looking ahead, we expect quality of weight loss to displace raw loss as the benchmark by 2027, with muscle-sparing data becoming a gating factor for late-stage differentiation. The oral race is likely to consolidate around a small number of small-molecule winners that solve bioavailability at scale, while China-originated assets increasingly populate Western late-stage pipelines through licensing deals.